molgramostim

Protein / enzyme therapeutic

Filedunder review

Evidence outlook · regulatory review

Autoimmune Pulmonary Alveolar Proteinosis: application under FDA review, decision date 2026-11-22

Molgramostim BLA PDUFA target action date (Priority Review, extended) (2026-11-22). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

IMPALA-2 (NCT04544293): People were randomized 1:1 to molgramostim or matching placebo with quadruple blinding, and the primary endpoint, change in lung gas transfer (DLCO), was measured by a standardized lung function test and met its significance test. The trial is of moderate size (164 people) for a rare disease.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Autoimmune Pulmonary Alveolar Proteinosis
NCT06431776 · Savara Inc.
2025-10-22 – 2027-12 · Autoimmune Pulmonary Alveolar Proteinosis
What this study did
NCT03482752 · Savara Inc.
2018-04-16 – 2021-01-14 · Autoimmune Pulmonary Alveolar Proteinosis
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT01729663 · Laboratorio Pablo Cassara S.R.L.
2009-04 – 2018-12 · Cutaneous Melanoma
What this study did
Phase 2 (6)
Autoimmune Pulmonary Alveolar Proteinosis
NCT02702180 · Savara Inc.
2016-03-21 – 2019-09-27 · Autoimmune Pulmonary Alveolar Proteinosis
What this study did
Other / comorbidity
NCT04569877 · University of Giessen
2020-09-24 – 2022-09-20 · Severe Acute Respiratory Syndrome (SARS) Pneumonia, COVID-19 Pneumonia
What this study did
NCT02595060 · University of Giessen
2016-06-01 – 2022-07-31 · ARDS
What this study did
NCT03597347 · Savara Inc.
2019-06-20 – 2020-10-02 · Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
What this study did
NCT03421743 · Savara Inc.
2018-03-01 – 2020-01-13 · Mycobacterium Infections, Nontuberculous
What this study did
NCT03435900 · Herlev Hospital
2018-02-14 – 2018-07-17 · Appendicitis Perforated
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05501340 · Second Affiliated Hospital of Soochow University
2022-09-01 – 2024-09-01 · Malignant Ascites
What this study did
Phase 1 (2)
Other / comorbidity
NCT07341360 · Oslo University Hospital
2025-10-13 – 2034-12-31 · Pseudomyxoma Peritonei
What this study did
NCT02468908 · Savara Inc.
2015-05 – 2015-10 · Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis, Acute Respiratory Distress Syndrome
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow molgramostim to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 3Autoimmune Pulmonary Alveolar ProteinosisRecruiting
Est. primary completion 2027-06 · NCT06431776 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 1Pseudomyxoma PeritoneiRecruiting
Est. primary completion 2029-12-31 · NCT07341360 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

22 November 2026FDA action dateMolgramostim BLA PDUFA target action date (Priority Review, extended)
US, FDA · Savara Inc. · Source ↗

Recent

26 June 2024Topline resultIMPALA-2 Phase 3 (NCT04544293) meets primary endpoint
Savara Inc. · Source ↗